Jeffrey S. Jay

Jeffrey S. Jay

Senior Associate
New York

Email jeffrey.jay@​hoganlovells.com

Phone +1 212 918 3633

Fax +1 212 918 3100

Practice groupCorporate

Jeff Jay represents leading life sciences companies on a variety of corporate and IP transactional matters.

As a member of the firm's Life Sciences and Health Care industry sector team, Jeff frequently advises on complex licensing and collaboration arrangements, M&A transactions, and other commercial deals, all exclusively in the life sciences space. In addition to having a deep industry knowledge, Jeff regularly leverages his prior experience as an intellectual property litigator in the pharmaceutical and chemical arts in his practice.

Education and admissions

Education

J.D., Vanderbilt Law School, 2014

B.A., Vanderbilt University, 2011

Memberships

New York State Bar Association

Bar admissions and qualifications

New York

Representative experience

Advised Novartis in connection with its collaboration with, and option to acquire, IFM Due, Inc.

Advised Gilead in connection with its collaboration with Agenus Inc. to develop and commercialize novel immuno-oncology therapies.

Advised Celgene in connection with its acquisition of Juno Therapeutics, Inc.

Advised Novartis in connection with its acquisitions of AveXis, Inc., Encore Vision, Inc., and IFM Tre, Inc.

Advised Gilead in connection with its collaboration with Hookipa Biotech AG to develop immunotherapies directed against hepatitis B virus and human immunodeficiency virus.

Advised Celgene in connection with the restructuring of its collaboration with Jounce Therapeutics, Inc.

Advised Novartis in connection with its collaboration with Cellular Biomedicine Group, Inc. to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Advised Gilead in connection with its collaboration with Tango Therapeutics, Inc. to discover, develop, and commercialize cancer immunotherapies.

Advised Jazz Pharmaceuticals in connection with its acquisition of Cavion, Inc.

Advised an international pharmaceutical company in connection with its acquisition of a priority review voucher.

Advised Novartis in connection with its collaboration with Homology Medicines, Inc. to use gene editing technology to develop ophthalmic and hemoglobinopathy disease treatments.

Regularly advises the National Eating Disorders Association on a variety of corporate and transactional matters.

Loading data